Amgen (AMGN) Convertible Debt (2009 - 2010)

Amgen (AMGN) recorded quarterly Convertible Debt of $2.2 billion in Q1 2010, down 51.22% quarter-over-quarter from $4.5 billion in Q4 2009.

Amgen (AMGN) Convertible Debt (2009 - 2010) Analysis & Trends

Amgen's Convertible Debt history runs 2 years deep, the most recent figure standing at $2.2 billion for Q1 2010.

In Q1 2010, Convertible Debt changed N/A year-over-year to $2.2 billion; the TTM figure through Mar 2010 stood at $2.2 billion (changed N/A YoY), while the FY2009 annual figure was $4.5 billion, changed N/A from the prior year.
Convertible Debt was $2.2 billion for Q1 2010 at Amgen, down from $4.5 billion in the prior quarter.
In the past five years, Convertible Debt ranged from a high of $4.5 billion in Q4 2009 to a low of $2.2 billion in Q1 2010.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Gsk	92,316,836.42 Bn	92,316,831.46 Bn	7.76 Bn
2	Eli Lilly	983.57 Bn	978.29 Bn	16.22 Bn
3	Johnson & Johnson	553.56 Bn	531.50 Bn	15.96 Bn
4	AbbVie	383.35 Bn	374.00 Bn	10.78 Bn
5	Merck	281.71 Bn	276.06 Bn	12.09 Bn
6	Amgen	182.20 Bn	170.16 Bn	5.87 Bn
7	Gilead Sciences	153.71 Bn	145.98 Bn	5.52 Bn
8	Pfizer	143.75 Bn	130.98 Bn	-1.21 Bn
9	Bristol Myers Squibb	109.71 Bn	99.25 Bn	8.07 Bn
10	Novartis Ag	108.28 Bn	107.60 Bn	-

Download Data